AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,120.50GBp
1 Jul 2015
Change (% chg)

-- (--)
Prev Close
4,120.50p
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,698,190
52-wk High
4,931.68p
52-wk Low
4,019.00p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. The Company's medicines include Crestor for... (more)

Overall

Beta: 0.53
Market Cap(Mil.): £50,887.49
Shares Outstanding(Mil.): 1,263.61
Dividend: 125.00
Yield (%): 4.43

Financials

  AZN.L Industry Sector
P/E (TTM): 62.55 35.50 39.29
EPS (TTM): 0.64 -- --
ROI: 3.21 17.07 16.27
ROE: 6.66 17.96 17.40
Search Stocks

AstraZeneca loses second top executive as Vectura gets new CEO

LONDON - AstraZeneca has lost a second senior executive in a fortnight with the departure of its respiratory and inflammatory medicines head James Ward-Lilley to become chief executive of lung drug specialist Vectura.

24 Jun 2015

UPDATE 1-AstraZeneca loses second top executive as Vectura gets new CEO

LONDON, June 24 - AstraZeneca has lost a second senior executive in a fortnight with the departure of its respiratory and inflammatory medicines head James Ward-Lilley to become chief executive of lung drug specialist Vectura.

24 Jun 2015

Vectura Group appoints AstraZeneca executive as CEO

June 24 - Respiratory drugs specialist Vectura Group Plc appointed AstraZeneca executive James Ward-Lilley as chief executive officer effective Oct. 1.

24 Jun 2015

BRIEF-Corline Biomedical says Corline Pharma connected to AstraZeneca BioVentureHub

* Corline Pharma has been connected to AstraZeneca BioVentureHub in Mölndal

18 Jun 2015

BRIEF-Astrazeneca names Pam Cheng as Executive VP, Operations and IT

* Appoints Pam Cheng as Executive Vice President, Operations and IT

16 Jun 2015

AstraZeneca R&D executive Morrison to lead cancer firm Syndax

LONDON, June 15 - AstraZeneca's outgoing chief medical officer and head of global late-stage drug development Briggs Morrison, whose departure from the British drugmaker was announced last week, is to head U.S. cancer firm Syndax Pharmaceuticals.

15 Jun 2015

BRIEF-DKSH and AstraZeneca expand relationship in South East Asia

* Says signed agreements with AstraZeneca to advance its business growth in Cambodia and Thailand through strategic outsourcing

11 Jun 2015

UPDATE 1-AstraZeneca R&D boss Morrison leaves to head private drugmaker

LONDON, June 10 - AstraZeneca's chief medical officer and head of global late-stage drug development Briggs Morrison is to leave the company, creating a gap at the top of the group's research operations.

10 Jun 2015

AstraZeneca research head Morrison leaves to head biotech firm

LONDON, June 10 - AstraZeneca's chief medical officer and head of global late-stage drug development Briggs Morrison is to leave the company, creating a gap at the top of the group's research operations.

10 Jun 2015

U.S. SEC says two stock brokers face criminal insider-trading charges

WASHINGTON - Two California-based stock brokers have been criminally charged with using material non-public information to trade in Ardea Biosciences Inc, a biotechnology firm later acquired by AstraZeneca, the U.S. Securities and Exchange Commission said on Tuesday.

09 Jun 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks